Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Esther Natalie OlivaMarta RivaPasquale NiscolaValeria SantiniMassimo BrecciaValentina GiaiAntonella PoloniAndrea PatriarcaElena CrisàIsabella CapodannoPrassede SalutariGianluigi RedaNicola CascavillaDario FerreroAttilio GuariniGiovanni TripepiGiuseppe IannìEmilio RussoAndrea CastelliBruno FattizzoGermana BeltramiMonica BocchiaAlfredo MolteniPierre FenauxUlrich GermingAlessandra RiccoGiuseppe Alberto Maria PalumboStefana ImperaNicola Di RenzoFlavia RivelliniFrancesco BuccisanoAspassia StamatoullasAnna Marina LiberatiAnna CandoniIlaria Maria DelfinoMaria Teresa ArcadiPatrizia CufariLorenzo RizzoIrene BovaMaria Grazia D'ErrigoGina ZiniRoberto LatagliataPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Eltrombopag was effective and relatively safe in low-risk MDS with severe thrombocytopenia. This trial is registered with ClinicalTrials.gov identifier: NCT02912208 and EU Clinical Trials Register: EudraCT No. 2010-022890-33.